16h
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...
A new mass spectrometry technique captures molecules of lower abundance in a sample, providing a more comprehensive sample ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback